Targeting chronic and neuropathic pain: The N-type calcium channel comes of age

Abstract

Summary:The rapid entry of calcium into cells through activation of voltage-gated calcium channels directly affects membrane potential and contributes to electrical excitability, repetitive firing patterns, excitation-contraction coupling, and gene expression. At presynaptic nerve terminals, calcium entry is the initial trigger mediating the release of neurotransmitters via the calcium-dependent fusion of synaptic vesicles and involves interactions with the soluble N-ethylmaleimide-sensitive factor attachment protein receptor complex of synaptic release proteins. Physiological factors or drugs that affect either presynaptic calcium channel activity or the efficacy of calcium-dependent vesicle fusion have dramatic consequences on synaptic transmission, including that mediating pain signaling. The Ntype calcium channel exhibits a number of characteristics that make it an attractive target for therapeutic intervention concerning chronic and neuropathic pain conditions. Within the past year, both U.S. and European regulatory agencies have approved the use of the cationic peptide Prialt for the treatment of intractable pain. Prialt is the first N-type calcium channel blocker approved for clinical use and represents the first new proven mechanism of action for chronic pain intervention in many years. The present review discusses the rationale behind targeting the N-type calcium channel, some of the limitations confronting the widespread clinical application of Prialt, and outlines possible strategies to improve upon Prialt's relatively narrow therapeutic window.

Inhibition of Transmitter Release and Attenuation of Anti-retroviral-associated and Tibial Nerve Injury-related Painful Peripheral Neuropathy by Novel Synthetic Ca2+ Channel Peptides

“…Alternative splice variants found on small diameter nociceptive neurons are associated with increased thermal and mechanical hyperalgesia (50,51). CaV2.2 is believed to be responsible for increased neurotransmitter release commonly associated with chronic and neuropathic pain conditions (1,2,52,53). Consistent with the role of CaV2.2 in pain signaling, genetic deletion, as well as pharmacologic block of CaV2.2, impairs nociceptive processing (3,54).…”

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

“…NVDCCs regulate presynaptic release of transmitters at many synapses (Snutch, 2005). The NVDCC blocker ziconotide is a powerful analgesic drug approved for the treatment of severe chronic pain in humans (McGivern 2007), and other NVDCC blockers are being developed for use in humans to treat stroke and pain (Giordanetto et al, 2011).…”

The N-type calcium channel is a novel target for treating alcohol use disorders

“…The N-type calcium channel is being actively targeted by medications development programs for the treatment of pain. 55 If these programs are successful there is a real possibility that N-type calcium channel blockers could be tested as a treatment for alcoholism in human trials.…”